A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis
← catalyst calendarSponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.
Phase
Phase 3
Status
Completed
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
63actual
Sites
34
Countries
Belgium, Canada, France +8
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-11-22 | actual | When the study began enrolling |
| Primary completion | 2026-05-01 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-05-01 | actual | The whole study's end, after follow-up |
| First posted | 2023-03-24 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-03 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Ulcerative Colitis
Interventions
- Drug: Mirikizumab IV — also filed as LY3074828
- Drug: Mirikizumab SC — also filed as LY3074828
Primary outcome
what the primary-completion date above is the date OFPercentage of Participants with modified Mayo score (MMS) Clinical Remission at Week 52 among the Week 12 Clinical Responders
measured Baseline to Week 52
Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed